Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Medtronic
Express Scripts
Colorcon
AstraZeneca

Last Updated: May 21, 2022

NATROBA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Natroba patents expire, and what generic alternatives are available?

Natroba is a drug marketed by Parapro Llc and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-seven patent family members in twenty-eight countries.

The generic ingredient in NATROBA is spinosad. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the spinosad profile page.

DrugPatentWatch® Generic Entry Outlook for Natroba

Natroba was eligible for patent challenges on January 18, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 28, 2024. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for NATROBA
Drug patent expirations by year for NATROBA
Drug Prices for NATROBA

See drug prices for NATROBA

Drug Sales Revenue Trends for NATROBA

See drug sales revenues for NATROBA

DrugPatentWatch® Estimated Generic Entry Opportunity Date for NATROBA
Generic Entry Date for NATROBA*:
Constraining patent/regulatory exclusivity:
FOR THE TOPICAL TREATMENT OF SCABIES INFESTATIONS IN ADULT AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER
NDA:
Dosage:
SUSPENSION;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NATROBA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AccelovancePhase 3
ParaPRO LLCPhase 3
Concentrics ResearchPhase 3

See all NATROBA clinical trials

US Patents and Regulatory Information for NATROBA

NATROBA is protected by one US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of NATROBA is See Plans and Pricing.

This potential generic entry date is based on FOR THE TOPICAL TREATMENT OF SCABIES INFESTATIONS IN ADULT AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting NATROBA

Formulations for controlling human lice
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.

FDA Regulatory Exclusivity protecting NATROBA

FOR THE TOPICAL TREATMENT OF SCABIES INFESTATIONS IN ADULT AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NATROBA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 See Plans and Pricing See Plans and Pricing
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 See Plans and Pricing See Plans and Pricing
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NATROBA

See the table below for patents covering NATROBA around the world.

Country Patent Number Title Estimated Expiration
Ukraine 65624 ПРЕПАРАТ ДЛЯ УХОДА ЗА ВОЛОСАМИ (ВАРИАНТЫ) И СПОСОБ БОРЬБЫ С ПЕДИКУЛЕЗНЫМ ПОРАЖЕНИЕМ ЧЕЛОВЕКА С ПРИМЕНЕНИЕМ СПИНОЗИНА (ВАРИАНТЫ);ПРЕПАРАТ ДЛЯ ДОГЛЯДУ ЗА ВОЛОССЯМ (ВАРІАНТИ) ТА СПОСІБ БОРОТЬБИ З ПЕДИКУЛЬОЗНИМ УРАЖЕННЯМ ЛЮДИНИ ІЗ ЗАСТОСУВАННЯМ СПІНОЗИНУ (ВАРІАНТИ) (PEDICULICIDAL FORMULATION FOR HAIR CARE (VARIANTS) AND METHODS OF CONTROLLING LICE INFESTATION USING SPINOSYN (VARIANTS)) See Plans and Pricing
World Intellectual Property Organization (WIPO) 0001347 See Plans and Pricing
Algeria 1375 Composés de macrolides. See Plans and Pricing
Brazil 0201412 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NATROBA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0375316 06C0047 France See Plans and Pricing PRODUCT NAME: SPINOSAD; REGISTRATION NO/DATE IN FRANCE: 2060098 DU 20060628; REGISTRATION NO/DATE AT EEC: 9275/B DU 20011023
0375316 350009 Netherlands See Plans and Pricing
0375316 C350009 Netherlands See Plans and Pricing PRODUCT NAME: SPINOSAD, DESGEWENST IN DE VORM VAN EEN ZOUT; NATL. REGISTRATION NO/DATE: 12363 N 20020913; FIRST REGISTRATION: SE 4511 20020204
0375316 SPC/GB02/028 United Kingdom See Plans and Pricing PRODUCT NAME: SPINOSAD; REGISTERED: CH W 6020 20010313; UK 0714 20020227
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Express Scripts
Mallinckrodt
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.